TP53, tumor protein p53, 7157

N. diseases: 2494; N. variants: 527
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE Yet, less is known about another hotspot p53 mutant, R249S (p53-R249S). p53-R249S is the sole hotspot mutation in hepatocellular carcinoma (HCC) that is highly associated with chronic hepatitis B virus (HBV) infection and dietary exposure to aflatoxin B1 (AFB1). 30608603 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE PRLH1 is highly expressed in p53-mutated hepatocellular carcinoma (HCC) samples and promotes cell proliferation in p53-mutated HCC cells, and its transcription is promoted by NF-Y and suppressed by p53. 31486214 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE Furthermore, we observe that Nup155 and FTSJ1 are p53 repression targets and accordingly find a correlation between the p53 status, Nup155 and FTSJ1 expression in murine and human hepatocellular carcinoma. 31089132 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE Moreover, apoptosis level and the protein level of p53 pathway were determined to reveal the mechanism of RFX5 in driving HCC development. 31188160 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Interaction between SIRT7 and p53 were studied in HCC cell lines. 31196136 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Moreover, the cytotoxic activity of C3 was examined in two other hepatocellular carcinoma (HCC) cell lines with different p53 status including Huh-7 cells (p53-mutant) and Hep3B cells (p53-null). 31354481 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE The area under curve for AS signature was 0.806 in all HCC and 0.944 in TP53 mutated HCC samples at 2000 days of OS. 31099827 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE This study investigated the efficacy of Toxoplasma GRA16, which binds to herpes virus-associated ubiquitin-specific protease (HAUSP), in anticancer treatment, and whether the expression of GRA16 in genetically modified hepatocellular carcinoma (HCC) cells (GRA16-p53-wild HepG2 and GRA16-p53-null Hep3B) regulates PTEN because alterations in phosphatase and tensin homologue (PTEN) and p53 are vital in liver carcinogenesis and the abnormal p53 gene appears in HCC. 30834688 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Immunohistochemical staining for p53 was negative in CLC, although ≤10% positive in the coexistent HCC-like area. 31261448 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Here, we demonstrated that glycogen synthase 2 (GYS2) restricted tumor growth in hepatitis B virus-related HCC via a negative feedback loop with p53. 30584071 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE Mutations in p53 are a common oncogenic driver in HCC but not in FL‑HCC. 31322272 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE Western blot results showed that the knockdown of PSMD4 blocked the expression of cyclooxygenase 2 (COX2), phosphorylated Sarcoma tyrosine kinase (P-SRC) and Bcl-2, but improved the levels of p53 and Bax in HCC, lung cancer, colorectal cancer, breast cancer and endometrial cancer cell lines. 30930224 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE We identified 5 genes (WNK2, RUNX1T1, CTNNB1, TSC1, and TP53) harboring somatic mutations that correlated with early tumor recurrence after curative resection in 182 primary HCC samples. 31349001 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE The performance of texture features in differentiating the P53 mutations of HCC was assessed using receiver operating characteristic analysis. 31163452 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE PPPDE1 promotes hepatocellular carcinoma development by negatively regulate p53 and apoptosis. 30426280 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE Majority of AFB1 associated hepatocellular cancer cases carry TP53 mutant DNA, which is an indicator of AFB1 exposure, as well as hepatocellular cancer risk. 30594067 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Quercetin, an antioxidant flavonoid, has been known that it can induce the cell cycle arrest and apoptosis of hepatocellular carcinoma (HCC) cells by the stabilization or induction of p53. 30661409 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Moreover, Lgr5 suppressed Dox-induced apoptosis via the p53 pathway and attenuated the cytotoxicity of Dox to HCC. 31244936 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE The role of p53 was further assessed by abrogation of the ATGL-mediated effects upon p53 silencing or in p53-null hepatocarcinoma Hep3B cells. 30367149 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 AlteredExpression disease BEFREE The Na+/K+‑ATPase inhibitor cinobufagin exhibits numerous anticancer effects on hepatocellular carcinoma (HCC) cells expressing wild‑type p53 via inhibition of aurora kinase A (AURKA) and activation of p53 signaling. 30942456 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Epigenetic silencing of ALX4 regulates microcystin-LR induced hepatocellular carcinoma through the P53 pathway. 31132711 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 GeneticVariation disease BEFREE We searched for pathogenic variants in TP53 in a 14 year-old female diagnosed with fibrolamellar hepatocellular carcinoma, a rare subtype of hepatocellular carcinoma. 28477317 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE The GSEA revealed that PON1 was associated with several hepatocellular carcinoma-related pathways, including the cell cycle, DNA replication, gap junction and p53 downstream pathways. 30477582 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Here we found that suppressing TIP60 inhibited p53 K120 acetylation and thus rescued apoptosis induced by glucose deprivation in hepatocellular cancer cells. 29174981 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
1.000 Biomarker disease BEFREE Moreover, recent researches reported increasing pathways and mechanisms related to ferroptosis in HCC such as TP53 and Rb, and strategies to improve sorafenib resistance by targeting ferroptosis. 30167889 2018